Senores Pharma.

Why is Senores Pharmaceuticals Ltd falling/rising?

As of 17-Aug, Senores Pharmaceuticals Ltd's stock price is rising to 1,544.20, up 4.54%, driven by strong financial growth and increased institutional investor interest. The stock has significantly outperformed the market, achieving a 52-week high and a remarkable annual return of 128.87%.

As of 17-Aug, Senores Pharmaceuticals Ltd's stock price is rising, currently at 1,544.20, which reflects an increase of 67.0 or 4.54%. This upward movement is supported by several positive factors. The stock has outperformed the sector by 4.84% today and reached a new 52-week high of Rs. 1549.45, indicating strong market interest. Over the past week, the stock has gained 8.59%, and in the last month, it has risen by 10.34%, significantly outperforming the Sensex, which has seen a decline of 1.04% and 0.54% respectively.<BR><BR>The company's financial health is also a contributing factor to the stock's rise. Senores Pharmaceuticals has demonstrated impressive growth, with net sales increasing at an annual rate of 71.70% and operating profit growing at 108.34%. Additionally, the company has reported positive results for the last five consecutive quarters, with net sales for the first nine months reaching Rs. 526.35 crore and a profit after tax of Rs. 93.99 crore.<BR><BR>Furthermore, there has been an increase in institutional investor participation, with their stake rising by 3.14% in the previous quarter, indicating confidence from more sophisticated investors. This is complemented by the stock's remarkable performance over the past year, generating a return of 128.87%, which is significantly higher than the broader market returns.<BR><BR>Despite some concerns regarding its valuation, as indicated by a high enterprise value to capital employed ratio, the overall positive financial indicators and market performance are driving the stock's rise.

Which are the latest news on Senores Pharma.?

Should I buy, sell or hold Senores Pharmaceuticals Ltd?

What does Senores Pharma. do?

Senores Pharmaceuticals Ltd is a Small Cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of 180 Cr and a net profit of 31 Cr for June 2026. It was incorporated in 2017 and became a public company in 2023, with a market cap of INR 6,848 Cr.

Overview:<BR>Senores Pharmaceuticals Ltd operates in the Pharmaceuticals & Biotechnology industry and is classified as a Small Cap company.<BR><BR>History:<BR>Senores Pharmaceuticals Ltd was originally incorporated as "Senores Pharmaceuticals Private Limited" in 2017. The company transitioned to a Public Limited Company and changed its name to "Senores Pharmaceuticals Limited" in 2023. The most recent quarterly results reported net sales and net profit for June 2026.<BR><BR>Financial Snapshot:<BR>Net Sales: 180 Cr (Quarterly Results - Jun 2026) <BR>Net Profit: 31 Cr (Quarterly Results - Jun 2026) <BR>Market Cap: INR 6,848 Cr (Small Cap)<BR><BR>Key Metrics:<BR>P/E: 54.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.20 <BR>Return on Equity: 12.36% <BR>Price to Book: 7.39 <BR><BR>Contact Details:<BR>Details: No Company Details Available <BR>Registrar Address: Not available.

Who are the peers of the Senores Pharma.?

Senores Pharma's peers include Orchid Pharma, P & G Health Ltd, Strides Pharma, Aarti Pharma, Sanofi India, Supriya Lifesci., SPARC, Innova Captab, FDC, and Bliss GVS Pharma. Key metrics show Senores Pharma has excellent growth and a good capital structure, with a 1-year return of 119.04%, while Bliss GVS Pharma leads in returns at 200.29% and Sanofi India has the lowest at -35.74%.

Peers: The peers of Senores Pharma are Orchid Pharma, P & G Health Ltd, Strides Pharma, Aarti Pharma, Sanofi India, Supriya Lifesci., SPARC, Innova Captab, FDC, and Bliss GVS Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at P & G Health Ltd and Sanofi India, while Good management risk is found at Innova Captab and Supriya Lifesci., Average management risk is present at Strides Pharma, Aarti Pharma, SPARC, and FDC, and Below Average management risk is noted at Orchid Pharma. In terms of Growth, Excellent growth is seen at Senores Pharma and SPARC, Good growth is observed at Strides Pharma, while Below Average growth is found at P & G Health Ltd, Orchid Pharma, Aarti Pharma, Sanofi India, Supriya Lifesci., and FDC. For Capital Structure, Excellent capital structure is noted at P & G Health Ltd, Sanofi India, Aarti Pharma, Supriya Lifesci., and Innova Captab, while Good capital structure is found at Senores Pharma, Average capital structure is seen at SPARC, and Below Average capital structure is present at Orchid Pharma, Strides Pharma, and FDC.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Bliss GVS Pharma at 200.29%, while the peer with the lowest 1-year return is Sanofi India at -35.74%. Senores Pharma's own 1-year return is significantly higher at 119.04%. Additionally, FDC has a negative six-month return of -4.63%.

How big is Senores Pharma.?

As of 14th August, Senores Pharmaceuticals Ltd has a market capitalization of 6,796.13 Cr, with recent net sales of 688.11 Cr and a net profit of 126.37 Cr over the last four quarters.

As of 14th August, <BR><BR>Market Cap: Senores Pharmaceuticals Ltd has a market capitalization of 6,796.13 Cr, categorizing it as a Small Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 688.11 Cr, while the sum of Net Profit for the same period is 126.37 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period for the latest annual data is March 2025. Shareholder's Funds stand at 786.18 Cr, and Total Assets are valued at 1,208.19 Cr.

Are Senores Pharmaceuticals Ltd latest results good or bad?

Senores Pharmaceuticals Ltd's latest results show strong year-on-year revenue growth of 30.60% and a net profit increase of 55.70%, but there was a sequential profit decline of 2.82% and rising costs, indicating mixed performance overall. Investors should consider both the positive revenue trends and the challenges ahead.

Senores Pharmaceuticals Ltd's latest results present a mixed picture. On the positive side, the company achieved a net profit of ₹30.72 crores for Q1 FY27, which is a significant increase of 55.70% year-on-year. Additionally, revenue grew by 30.60% compared to the same quarter last year, reaching ₹180.21 crores, marking the highest quarterly sales on record for the company.<BR><BR>The operating margin also showed improvement, rising to 29.83%, which is an increase of 269 basis points from the previous quarter. This indicates better operational efficiency and cost management.<BR><BR>However, there are some challenges to consider. The net profit saw a sequential decline of 2.82% compared to the previous quarter, which raises concerns about profitability despite the strong revenue growth. The company is also facing elevated interest costs and a significant drop in other income, which contributed to the decline in overall profitability.<BR><BR>Overall, while the revenue growth and operational improvements are commendable, the sequential profit decline and rising costs suggest that the company is navigating some headwinds. Investors may want to weigh these factors carefully when assessing the company's performance.

When is the next results date for Senores Pharmaceuticals Ltd?

The next results date for Senores Pharmaceuticals Ltd is July 27, 2026.

The next results date for Senores Pharmaceuticals Ltd is scheduled for July 27, 2026.

How has been the historical performance of Senores Pharma.?

Senores Pharma experienced significant growth from March 2024 to March 2025, with net sales rising from 214.52 Cr to 398.25 Cr and profit after tax increasing from 32.71 Cr to 58.34 Cr, despite higher raw material and employee costs. Total assets and liabilities both grew to 1,208.19 Cr, while cash flow from financing activities improved significantly.

Answer:<BR>The historical performance of Senores Pharma shows significant growth in various financial metrics from March 2024 to March 2025.<BR><BR>Breakdown:<BR>Senores Pharma's net sales increased substantially from 214.52 Cr in March 2024 to 398.25 Cr in March 2025, reflecting strong operational growth. Total operating income followed the same trend, rising to 398.25 Cr from 214.52 Cr. However, raw material costs surged to 91.64 Cr from 31.96 Cr, and employee costs also rose to 60.37 Cr from 35.46 Cr, contributing to a total expenditure of 308.55 Cr, up from 172.92 Cr. Operating profit (PBDIT) improved significantly to 108.96 Cr from 44.42 Cr, with profit before tax reaching 70.57 Cr compared to 24.95 Cr the previous year. Profit after tax also saw an increase to 58.34 Cr from 32.71 Cr. The company's total assets grew to 1,208.19 Cr from 606.92 Cr, while total liabilities increased to 1,208.19 Cr from 606.92 Cr as well. Cash flow from operating activities remained negative at -45.00 Cr, but cash flow from financing activities turned positive at 573.00 Cr, leading to a net cash inflow of 97.00 Cr, up from 7.00 Cr. Overall, Senores Pharma demonstrated robust growth in revenue and profitability, alongside increased asset and liability levels.

Is Senores Pharma. overvalued or undervalued?

As of September 18, 2025, Senores Pharma is considered very expensive and overvalued with a PE ratio of 56.49 and lower returns compared to peers, despite a year-to-date stock performance of 25.84% against the Sensex's 6.24%.

As of 18 September 2025, the valuation grade for Senores Pharma has moved from expensive to very expensive, indicating a significant shift in its market perception. The company is currently deemed overvalued, with a PE ratio of 56.49, an EV to EBIT of 44.43, and an EV to EBITDA of 36.09. These ratios are considerably higher than its peers, such as Sun Pharma, which has a PE ratio of 34.46 and an EV to EBITDA of 23.34, and Cipla, which boasts a more attractive PE ratio of 23.65 and an EV to EBITDA of 16.67.<BR><BR>In comparison to its industry, Senores Pharma's financial metrics suggest that it is not only overvalued but also lacks competitive returns, as evidenced by its ROE of 7.45% and ROCE of 10.18%. While the stock has outperformed the Sensex year-to-date with a return of 25.84% compared to the Sensex's 6.24%, the overall valuation metrics indicate that investors may be paying a premium that is not justified by the company's financial performance.

What is the technical trend for Senores Pharma.?

As of March 10, 2025, Senores Pharma's technical trend is neutral with no strong signals, as indicators like MACD and RSI show a sideways movement, despite recent outperformance against the Sensex.

As of 10 March 2025, the technical trend for Senores Pharma has changed to sideways. The current technical stance is neutral, with no strong bullish or bearish signals evident. The MACD, RSI, and other indicators do not provide clear directionality on the weekly or monthly time frames. The Dow Theory indicates no trend on the weekly and monthly levels, and the On-Balance Volume (OBV) also shows no trend. The stock's recent performance has outpaced the Sensex over the past week and month, but the year-to-date return is negative, suggesting mixed sentiment. Overall, the lack of definitive indicators keeps the outlook neutral.

Who are the top shareholders of the Senores Pharma.?

The top shareholders of Senores Pharma include promoter Swapnil Jatin Shah with 7.72%, Aditya Birla Sun Life Insurance Company Limited at 3.71%, mutual funds with 3.23%, foreign institutional investors holding 4.17%, and individual investors collectively owning 31.43%.

The top shareholders of Senores Pharma include the promoters, who are the majority shareholders. The promoter with the highest holding is Swapnil Jatin Shah, owning 7.72% of the company. Additionally, Aditya Birla Sun Life Insurance Company Limited is the highest public shareholder, holding 3.71%. The company also has mutual funds holding 3.23% across five schemes and foreign institutional investors (FIIs) holding 4.17% through 21 different entities. Individual investors collectively hold 31.43% of the shares.

Has Senores Pharma. declared dividend?

No Dividend History Available